All News

Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.

Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma.

The phase 3 EMERALD-3 trial met its primary end point of PFS with durvalumab, tremelimumab, lenvatinib, and TACE in patients with unresectable HCC.

Investigators of a prospective validation study highlighted the potential of a urine-based assay to reduce surgical biopsies deemed unnecessary.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

The totality of evidence from the phase 2 ZUMA-2 study formed the basis of the regulatory decision.

The FDA has extended the PDUFA action date to July 6, 2026, for approving Orca-T across different hematologic malignancies.

Ryan H. Moy, MD, PhD, is the principal investigator of a phase 2 trial evaluating defactinib plus avutometinib in patients with diffuse gastric/GEJ carcinoma.

Phase 2 Cyto-KIK findings showed that a subset of patients with high-risk kidney cancer exhibited responses and underwent monitoring post-cabozantinib.

The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

A statistically significant pCR rate was noted in patients with HER2+ breast cancer treated with anbenitamab injection and albumin-bound docetaxel.

BiliSeqV2/V3 improved neoplastic bile duct stricture identification compared with pathology alone, according to a study from UPMC investigators.

The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-versus-host-disease with gastrointestinal involvement.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

The project will be focused on increasing awareness and early detection of the disease and generate high-quality data to inform improvement of care.

A panel of oncologists, pharmacists, and physician assistants discussed prevalent regimens for patients with recurrent endometrial cancer.

The SkinJect data set found about an 80% overall response rate for patients with nodular basal cell carcinoma receiving 200µg of doxorubicin microneedle array.

Results from the phase 1/2 ReFocus trial demonstrated positive activity from lirafugratinib in the various pretreated, FGFR2-mutated cholangiocarcinoma populations.

Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.

Three experts in surgery, radiation, and integrative care disclosed the most salient advances and keen insights in their respective fields.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Jesse Fann, MD, MPH, spoke about what he hopes to accomplish during the 2-year term of his APOS presidency.

The latest clinical insights on endometrial cancer management were highlighted during a round table discussion.

Experts in genitourinary oncology outlined factors to consider when sequencing immunotherapy, tyrosine kinase inhibitors, and other RCC therapies.

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

Phase 3 ENVISION trial data revealed a 72.2% probability of remaining event-free among responders to UGN-102 with non-muscle invasive bladder cancer.

Patients with stage IIA to IIIA NSCLC identified as low risk per LAMPAD criteria may be candidates for treatment de-escalation with nivolumab.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.